Efficacy and Safety of Single-inhaler Triple Therapy Containing Dual Bronchodilator With Corticosteroids Compared to Monotherapy, Dual Therapy, or Open Triple Therapy in Moderate/Severe COPD: A Systematic Literature Review

Riesco Miranda, Juan Antonio; Calle Rubio, Myriam; Díaz Pérez, David; López-Campos, Jose Luis; Trigueros Carrero, Juan Antonio; Celli, Bartolomé

doi:10.1016/j.arbres.2023.10.006

Archivos de Bronconeumología

ISSN: 0300-2896

Archivos de Bronconeumologia is a scientific journal that preferentially publishes prospective original research articles whose content is based upon results dealing with several aspects of respiratory diseases such as epidemiology, pathophysiology, clinics, surgery, and basic investigation. Other types of articles such as reviews, editorials, a few special articles of interest to the society and the editorial board, scientific letters, letters to the Editor, and clinical images are also published in the Journal. It is a monthly Journal that publishes a total of 12 issues and a few supplements, which contain articles belonging to the different sections.

All the manuscripts received in the Journal are evaluated by the Editors and sent to expert peer-review while handled by the Editor and/or an Associate Editor from the team. The Journal is published monthly in English.

Manuscripts will be submitted electronically using the following web site: https://www.editorialmanager.com/ARBR/, link which is also accessible through the main web page of Archivos de Bronconeumologia.

Access to any published article, is possible through the Journal's web page as well as from PubMed, Science Direct, and other international databases. Furthermore, the Journal is also present in Twitter and Facebook. The Journal expresses the voice of the Spanish Respiratory Society of Pulmonology and Thoracic Surgery (SEPAR) as well as that of other scientific societies such as the Latin American Thoracic Society (ALAT) and the Iberian American Association of Thoracic Surgery (AICT).

Authors are also welcome to submit their articles to the Journal's open access companion title, Open Respiratory Archives.

Archivos de Bronconeumologia has received the new Impact Factor (JCR). The impact factor has risen from 6.333 in 2021 to 8 in the last evaluated year, 2022.
It is needed to be a member of SEPAR or have a subscription to access full texts of articles published last year. Abstracts are available for all visitors.

Indexed in:

Current Contents/Clinical Medicine, JCR SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, SCOPUS, IBECS

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2022

Citescore

CiteScore measures average citations received per document published.

Citescore 2022

2.8

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2022

0.434

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2022

0.437

View more metrics

Open Access Option

Journal Information

Previous article | Next article

Vol. 60. Issue 1.

Pages 55-58 (January 2024)

Export reference

Download PDF

More article options

Statistics

Vol. 60. Issue 1.

Pages 55-58 (January 2024)

Scientific Letter

DOI: 10.1016/j.arbres.2023.10.006

Efficacy and Safety of Single-inhaler Triple Therapy Containing Dual Bronchodilator With Corticosteroids Compared to Monotherapy, Dual Therapy, or Open Triple Therapy in Moderate/Severe COPD: A Systematic Literature Review

Visits

677

Download PDF

Juan Antonio Riesco Mirandaa,

Corresponding author

jantonio.riesco@gmail.com

Corresponding author.

, Myriam Calle Rubiob, David Díaz Pérezc, Jose Luis López-Camposd, Juan Antonio Trigueros Carreroe, Bartolomé Cellif

a Servicio de Neumología, Hospital San Pedro de Alcántara, Ciberes, Cáceres, Spain

b Servicio de Neumología, Hospital Universitario Clínico San Carlos, Madrid, Spain

c Servicio de Neumología y Cirugía Torácica, Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain

d Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/Universidad de Sevilla, Sevilla, Spain

e Centro de salud Menasalbas, Menasalbas, Toledo, Spain

f Pulmonary and Critical Care Division, Brigham and Women's Hospital, Harvard University Medical School, Boston, MA, USA

This item has received

677 Visits

Article information

Full Text

Bibliography

Download PDF

Statistics

Tables (2)

Table 1. Summary of the Main Results of the Meta-analysis at 52 Weeks. Green Color Represents Comparisons With Higher Level of Evidence in Favor of Single-inhaler Triple Therapy (Meta-analysis or Clear Effect From Randomized Clinical Trials). Yellow Color Depicts Contradictory Results or an Absence of Difference Between Treatment Groups Across Several Comparisons. Light Blue Color Indicates Lacking Data. For Each Result the Study References are Provided.

Table 2. Main Results of Single-inhaler Triple Therapy at 52 Weeks According to COPD Medication at Screening. Green Color Represents Comparisons With Statistically Significant Evidence in Favor of Single-inhaler Triple Therapy. Yellow Color Depicts Contradictory Results or an Absence of Difference Between Treatment Groups. Light Blue Color Indicates Lacking Data.